Bioequivalence Pilot Study of Candesartan Cilexetil Tablet 16 mg Produced by PT Kimia Farma Tbk Compared to Blopress® Tablet 16 mg Produced by PT. Takeda Indonesia, Bekasi, Indonesia Under License of Takeda Pharmaceutical Company Limited, Osaka, Japan.

Tahapan Penelitian : Complete
Sponsor:
Mitra Pelaksana:
Equitrust Lab - PT Kimia Farma Diagnostika
No Registry
INA-20HHW1T
Tanggal Input Registry : 02-09-2024

01-04-2023
AUC0-t , Cmax
AUC0-inf , tmax, half life
 
Bioequivalence Pilot Study of Candesartan Cilexetil Tablet 16 mg Produced by PT Kimia Farma Tbk Compared to Blopress® Tablet 16 mg Produced by PT. Takeda Indonesia, Bekasi, Indonesia Under License of Takeda Pharmaceutical Company Limited, Osaka, Japan.
Bioequivalence Pilot Study of Candesartan Cilexetil Tablet 16 mg Produced by PT Kimia Farma Tbk Compared to Blopress® Tablet 16 mg Produced by PT. Takeda Indonesia, Bekasi, Indonesia Under License of Takeda Pharmaceutical Company Limited, Osaka, Japan.
Interventional
Candesartan Cilexetil Tablet 16 mg by PT. Kimia Farma Tbk
6
 

Inclusion Criteria:

The inclusion criteria for this study include: 1) Signed informed consent; 2) Healthy based on clinical laboratory tests (routine hematology, liver function, kidney function, blood glucose, urinalysis, hepatitis B (HBsAg), hepatitis C (Anti-HCV) and HIV (Anti-HIV), medical history, and physical examination); 3) Male and female subjects (if female, consider the risks for women of childbearing age and perform pregnancy tests); 4) Age between 18-55 years; 5) Normal weight range according to Body Mass Index (BMI) 18-25 kg/m2); 6) Vital signs within the following ranges: systolic blood pressure 110-129 mmHg, diastolic blood pressure 70-84 mmHg, normal pulse rate 60-90 bpm, oxygen saturation (SpO2) in the normal range of 95- 100%, and normal respiratory rate of 12-20/min.

Exclusion Criteria:

The exclusion criteria for this study include: 1) Smoking more than 10 cigarettes per day; 2) Pregnant or breastfeeding women. Pregnancy tests was performed during screening and prior to the administration of the investigational or comparator drug; 3) History of kidney or liver disease, or history of allergy, hypersensitivity or contraindication to the investigational bioequivalence drug (Candesartan Cilexetil); 4) Clinically significant hematological abnormalities; 5) Abnormal electrocardiogram (ECG); 6) Difficulty accessing veins in the left or right arm; 7) History of significant ongoing clinically or medically significant chronic or acute illness; 8) History of drug or alcohol abuse within the past 12 months (1 year) prior to screening for this study; 9) Positive serology test results for Hepatitis B (HBsAg), Hepatitis C (anti-HCV), HIV (anti-HIV). 10) Positive rapid antigen test results for SARS-CoV-2 (if the BE study is conducted during a pandemic). 11) History or condition that can affect drug kinetics. 12) Use of drugs or dietary supplements no more than 7 days since the start of the study. 13) Participation in previous clinical trials no more than 3 months from the start of the study. 14) Blood donation or blood loss of more than 300 ml within 3 months from the start of the study.
 
KET-544/UN2.F1/ETIK/PPM.00.02/2023
Not applicable
Not applicable
Nungky Tri Yunica, S.T (lab.equitrust@gmail.com)